Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drugs in Development, 2021

Published	Pages	Publisher	Report code
Oct 2021	43	Global Markets Direct	ASDR-593511

Published: Oct 2021 - Pages : 43 - Publisher : Global Markets Direct - Report code : ASDR-593511

Addex Therapeutics Ltd
Camino Pharma LLC
Denovo Biopharma LLC
Eli Lilly and Co
Gate Neurosciences Inc
Mavalon Therapeutics Ltd (Inactive)
Noema Pharma AG
Taisho Pharmaceutical Holdings Co Ltd

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

This report can be of interest as well:

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Drugs in Development by Stages, Target, MoA, RoA, Molecule ...

Published: October, 2022 | Report code: ASDR-611913